Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Glencore profits fall 14% on weak coal prices; Keeps London listing

(Sharecast News) - Mining giant Glencore reported a fall in half-year profits, reflecting weaker coal prices and lower copper volumes, while the company also said it would retain its London listing after mulling a move to New York. Adjusted core earnings declined 14% to $5.4bn, while marketing operating profits slid 8% to $1.8bn, which the miner and commodities trader called a "solid" result against a macroeconomic environment affected by US tariff policy uncertainty and tensions in the Middle East.

The company also said it had abandoned plans to move its main listing to New York from London in what would have been yet another blow to the UK's reputation as a financial hub.

"Of the major global equity exchanges, the scale and depth of US capital markets is unrivalled, but having considered the costs and benefits, including in respect of indexation, we do not believe that becoming a US domestic issuer or having a sponsored American depositary receipt program would be value," it said.

Glencore last week reported lower first-half copper production and targeted $1bn in cost savings by the end of next year after a review of its industrial asset portfolio.

The miner and commodities trader said output was down 26% to 343,900 metric tons, mostly due to declining grades, and tightened its 2025 forecast to 850,000 to 890,000 tonnes from 850,000 to 910,000.

It also revised its long-term full-year marketing operating earnings to $2.3bn - $3.5bn from $2.2bn - $3.2bn after completing the sale of its agribusiness Viterra in July.

Production of cobalt, a key component in electric car batteries, rose 19% year on year to 18,900 tonnes.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.